Eiger BioPharmaceuticals (NASDAQ:EIGR) presented positive post-treatment results from its Phase 2 trial of lambda interferon monotherapy (LIMT) in patients with chronic hepatitis D virus (HDV).
The study enrolled 33 patients to evaluate the safety, tolerability, and efficacy of two LIMT dose levels in patients with chronic HDV infection. At 24 weeks post-treatment, 36% of patients receiving the 180 μg dose achieved a durable virologic response.
“The durable virologic response observed 24 weeks post-treatment with lambda may be a meaningful endpoint for discussions with regulatory agencies. Lambda is now being dosed in combination with lonafarnib and ritonavir in HDV-infected patients in the Phase 2 [combination therapy] study at the National Institutes of Health, and we look forward to end of treatment data later this year,” David Apelian, Eiger’s COO and executive medical officer, said in a statement.
There are currently no approved treatments for HDV, which is the most severe form of hepatitis.
